Tonix Pharmaceuticals Holding Corp. (TNXP) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Tonix Pharmaceuticals Holding Corp.'s filing signal turned positive.

Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. In August 2025, the company received FDA approval for TONMYA (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, launching it in November 2025 as the first new treatment for the condition in over 15 years. Tonix also markets two prescription products for acute migraine: Zembrace(R) SymTouch(R) and Tosymra(R). The company's development pipeline includes TNX-102 SL for major depressive disorder and acute stress disorder, TNX-1300 for cocaine intoxication, TNX-4800 for Lyme disease prevention, and TNX-1500 for organ transplant rejection and autoimmune diseases. Tonix aims to grow TONMYA, advance its pipeline, and pursue strategic business development opportunities.

Revenue is primarily driven by the sales of its commercialized products, TONMYA, Zembrace SymTouch, and Tosymra. The company's strategy is to grow sales of TONMYA and expand its commercial platform.